Company profile

AbbVie Inc.

NYSE:ABBVBiotechnology: Pharmaceutical Preparations

Drug pipeline (185)

AssetStageRevenueTrialsStatus
ABBV-257phase11no active trials
ABBV-3373phase21no active trials
ABBV-467phase11terminated
ABBV-744phase12active
ABEXINOSTATphase1_24no active trials

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (1910)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT03777059phase3completed2018-12-142020-06-19Allergan12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine
NCT00457795phase4completed2006-12-012009-02-01Allergan24-hour IOP-lowering Effect of Brimonidine 0.1%
NCT02472626phase1_2withdrawn2015-12-012016-07-01Wake Forest University Health Sciences6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT01162421phase4completed2010-09-012015-07-01AbbVie (prior sponsor, Abbott)A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure in Early Rheumatoid Arthritis
NCT03573297phase3completed2018-06-152022-09-05AbbVieA Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features

FDA applications (162)

ApplicationTypeApplicantProducts
ANDA 040117ANDAABBVIE INC
ANDA 065003ANDAABBVIE INC
ANDA 065025ANDAABBVIE INC
ANDA 071295ANDAABBVIE INC
ANDA 074638ANDAABBVIE INC